Bioidentical Hormones Boca Raton: The Approved Ones, and What the FDA Changed

Almost everything written about bioidentical hormones Boca Raton women read treats the word as a synonym for compounded. It is not. There are FDA-approved products that are chemically identical to the hormones your body makes, one of them combines both in a single capsule, and the FDA has now removed the warnings that kept a generation of women away from any of it.

Bioidentical hormones Boca Raton: what the word actually means

The marketing has made this word confusing, so start with what it describes. Bioidentical means the molecule is chemically identical to the one your own body makes. It says nothing about where the medicine was made, who made it, or whether anyone reviewed it.

The FDA uses that language itself. The approved progesterone label says the active ingredient “is synthesized from a starting material from a plant source and is chemically identical to progesterone of human ovarian origin”. An FDA-approved medicine, made in a regulated facility, describing itself in exactly the terms a compounding pharmacy would use.

So the real question was never bioidentical or not. It is whether the specific product you are prescribed has been through an approval process, with a known dose in every capsule and a label somebody can read. Those are different questions and the marketing has spent twenty years merging them.

The bioidentical products that carry an FDA approval

These exist, they are prescribed every day, and most women have never been told they are an option.

Micronized progesterone is approved and, per its label, chemically identical to the progesterone of human ovarian origin. It is indicated for preventing endometrial hyperplasia in postmenopausal women with a uterus who are receiving oestrogen, and for secondary amenorrhoea.

Estradiol is the principal oestrogen the body produces before menopause, and approved estradiol products come as tablets, patches, gels and vaginal preparations.

There is also a combination. Bijuva is an approved capsule containing both — “estradiol and progesterone… in which the estradiol is solubilized and the progesterone is micronized and suspended” — indicated “in a woman with a uterus for the treatment of moderate to severe vasomotor symptoms due to menopause”, at 0.5 mg estradiol with 100 mg progesterone, or 1 mg with 100 mg.

That last one is worth pausing on if you have been told the only way to get both hormones in bioidentical form is through a compounding pharmacy. There is an approved capsule that does it, with a fixed dose and a label.

The warnings the FDA removed, and when

If you decided against hormone therapy sometime after 2002, you decided against it on the strength of warnings that are no longer there.

It happened in two steps, and the second one is the one that counts. On 10 November 2025 the FDA announced it was removing the boxed warnings covering cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy, after what it called a comprehensive review of the scientific literature. That was the decision. The labels themselves then had to be rewritten and approved, which is what happened on 12 February 2026, when the FDA approved changed labeling for the first six products, one from each of the four categories of menopausal hormone therapy. Twenty-nine companies had submitted proposed changes.

You can check it on the product rather than take anyone’s word for it. The approved capsule that contains both estradiol and progesterone carries prescribing information revised 02/2026, and it records that its boxed warnings were removed that month. That is the change showing up where it actually matters.

The boxed warning about endometrial cancer was retained for systemic oestrogen-alone products, which is why progesterone is prescribed alongside oestrogen for a woman who still has a uterus.

The reason given matters as much as the change. Those warnings originated in the Women’s Health Initiative, a study whose average participant was 63 years old — in the FDA’s words, “over a decade past the average age of a woman experiencing menopause” — and which found a statistically non-significant increase in breast cancer diagnoses. A finding that did not reach significance, in a population much older than the women being treated, shaped a generation of prescribing.

The FDA Commissioner’s own words on the announcement were blunt: “Tragically, tens of millions of women have been denied the life-changing and long-term health benefits of hormone replacement therapy because of a medical dogma rooted in a distortion of risk.” The agency’s announcement also pointed to benefits for women who begin therapy within ten years of menopause. On the February approval he added that the action was “delivering on our promise to make sure women have accurate, scientifically grounded information about the potentially life-changing benefits of HRT”.

None of that means hormone therapy is right for everyone, and it does not remove the need for an individual assessment. It does mean the conversation you had with yourself in 2010 was based on information the FDA has since revised.

Where compounding fits, honestly

Compounded hormones have a legitimate place, and it is narrower than the way they are usually sold.

Compounding exists for the patient an approved product does not fit: an allergy to an excipient, a dose that is not manufactured, a form somebody cannot take. That is a real clinical need and it is why the law permits it.

What compounding is not is a better version of the approved product. The National Academies reviewed compounded bioidentical hormone therapy for the FDA and found “a lack of rigorous evidence of safety and effectiveness from well-designed or properly controlled clinical studies”, with the available information coming “mostly from low quality data, such as anecdotal claims, patient reports, and prescriber testimonies”. It concluded that widespread use poses a public health concern.

So the order here is approved first, compounded where an approved product genuinely will not do, and a reason given either way. If a clinic goes straight to a compounded pellet without telling you an approved option exists, that is worth asking about — and it is a question you are now equipped to ask anywhere.

How hormone therapy runs at Brazelia MedSpa

It starts with labs and a history rather than with a product. What is actually low, what your symptoms are, what else you take and what your risks are all come before any decision about what to prescribe.

Where an approved product fits, that is what is used, and you will be told which one and why. Where it does not, compounding is available and the reason for choosing it is explained rather than assumed. Either way you should leave knowing what you are taking, what it is expected to do and what will be watched.

Thyroid and metabolic markers are looked at in the same visit, because low energy, poor sleep and weight change have several possible causes and hormones are one of them rather than all of them. Those sit on the thyroid page and the metabolic labs page.

New patients start with a consultation, where what is worth testing and what the options actually are is discussed before anything is prescribed.

Frequently asked questions

Sources and how this page was built

The chemically-identical wording, the indications and the dosage strengths on this page are read from FDA-approved labeling for progesterone and for the estradiol-progesterone combination, revision 02/2026. The labeling change is read from two FDA announcements — the 10 November 2025 decision and the 12 February 2026 approval of the rewritten labels — and the compounding findings from the FDA’s page on the National Academies review. All read 28 September 2026. Benefit figures quoted in press coverage of those announcements are deliberately not reproduced here.

Why patients choose Brazelia MedSpa

This page is the best answer we can give. The easy version sells a pellet and never mentions that an approved capsule with the same two hormones exists. This one tells you it does, quotes the label that calls itself chemically identical, and says where compounding genuinely belongs — because you should be choosing between real options rather than between marketing claims.

Hormone therapy at Brazelia MedSpa is run by Khali Reed, CRNA, APRN, in a practice under the medical direction of Dr. Herbert R. Slavin, MD, on site rather than a name on a licence.

Brazelia MedSpa has treated patients from the same address in downtown Boca Raton for 18 years, near Mizner Park, and sees patients from across South Florida, from Delray Beach and Boynton Beach to Deerfield Beach and Fort Lauderdale. The programme is run by the same people every visit, which matters more on a medication you take for a year than on a treatment you have once.

Weight is also rarely treated as just weight here. Because Brazelia MedSpa runs hormone, metabolic, skin and regenerative programmes under one roof, thyroid, sleep, training load and the skin changes that follow a large weight reduction can be looked at in the same place, by people who are already talking to each other.

New patients start with a consultation, and nothing is prescribed on a first visit unless it is clinically appropriate and you want to proceed. You will hear what the label supports, what it does not, and what the plan would look like before anything is decided.

This page describes what published labels, regulatory records and peer-reviewed research report about these treatments. It is general health information, not medical advice, and it is not a substitute for a consultation. Whether any treatment is appropriate for you is a clinical judgement that depends on your history and examination.